Table 5. Summary of CD nanoparticles used for targeted and site specific delivery .
| CD-Type used | Drug/molecule | Formulation type | Target site/Cell line | Disease/ Disorder/Application | Ref. |
| PEGylated CD | SiRNA | Injectable preparation | Prostate | Cancer | 165 |
| Β-CD-bearing Gold-GlycoNP | Methotrexate | Gold NP | cDNA clone for the human galectin-3 | Cancer | 166 |
| Β-CD-poly(5-amido iso-phthalic acid) | Docetaxel | Magnetic NP | HeLa and MDA-MB-231 cancerous cell line cells | Cancer | 167 |
| lactoferrin-modified β-CD | Near-infrared fluorescent dye IR-775 chloride | Injectable NP | Brain | Neurological disease and as diagnostic reagents | 168 |
| Sulfobutyl ether β-CD | Naringenin | β-CD/chitosan NP | Ocular | Topical ophthalmic delivery | 98 |
| Polycationic amphiphilic cyclodextrin | Plasmid pCMVLuc VR1216 (6934bp) encoding luciferase | Nanocomplexes | HeLa or HepG2 cells. | Gene delivery | 169 |
| α-CD | doxorubicin hydrochloride | Supramolecular Hydrogels Based on PEG-PLA-Block Copolymer Micelles and α-CD | HeLa cells | Controlled release in Cancer | 170 |
| β-CD | Ibuprofen | Magnetic NP double coated with β-CD chitosan | HEPG-2, MCF-7 and BEL-1 | Magnetically targeted and controlled release | 171 |
| β-CD | Reservatrol | pH-sensitive nanoparticles loaded into microbubbles | Hepato-carcinoma (H22) cells | pH responsiveness, targeted treatment, and ultrasound tumor imaging | 172 |
| β-CD | Doxorubicin | NP | HeLa cells | Cancer | 173 |
CD, cyclodextrin; NP, nanoparticle.